VPC
MNPR icon

Vestal Point Capital’s Monopar Therapeutics MNPR Stock Holding History

Vestal Point Capital’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.01M Buy
75,727
+10,309
+16% +$638K 0.16% 58
2026
Q1 		$3.58M Buy
+65,418
New +$3.95M 0.1% 79

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vestal Point Capital's MNPR Position: Q2 2026 in Review

Vestal Point Capital increased its Monopar Therapeutics (MNPR) stake by 16% in Q2 2026, buying an estimated $638K and bringing the position to 75,727 shares worth $7.01M. The position accounts for 0.16% of the portfolio, ranked #58.

Vestal Point Capital first reported a position in MNPR in Q1 2026 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Vestal Point Capital held 75,727 shares of Monopar Therapeutics worth $7.01M as of Q2 2026.
  • Vestal Point Capital bought 10,309 Monopar Therapeutics shares in Q2 2026, an estimated $638K.
  • Monopar Therapeutics made up 0.16% of Vestal Point Capital's portfolio in Q2 2026, its #58 holding.
  • Vestal Point Capital first reported a position in Monopar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.